ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CRL
ICLR (72) MEDP (77) INCY (88) IQV (61) ⌘ Pro Terminal →

Charles River Laboratories International Inc. (CRL) — RQD Stock Rating Cockpit

$338.54 -5.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $334.36

Charles River Laboratories International Inc. (CRL) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $17.16B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Charles River Laboratories International Inc. (NYSE: CRL) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $338.54 (-5.81% 1D, market cap $17.16B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, CRL ranks #125 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRL compare to ICLR and MEDP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), CRL carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 0.4%. By comparison, ICLR (ICON plc) holds a B grade (72/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.18B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRL?
▼

Per CRL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001100682), Charles River Laboratories International Inc. generated $4.02B in revenue (-0.9% YoY), -$144.3M in net income, and $557.0M in free cash flow against $7.14B in total assets and $1.77B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $334.34 (-1.24%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 13.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B- · Rk D+
Cash (13)Whales (19)SEC (12)Macro (10)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$410 Bull$348 Base$271 Bear
📬 FREE CRL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRL)Realized 20D OHLCV Swing Band: ±8.4%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY CRL SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (30% of score)

20D Institutional Volume Accumulation (±8.4% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($557.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution10/20 pts (-10 pt drag)

Cannibal Buyback (-0.68% YoY Shares) & executive Form 4 sales trim 10 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$302.00+14.2% Next Q
Q2 (-2Q)
59
Grade C$344.87+8.4% Next Q
Q3 (-1Q)
61
Grade C$373.98-9.5% Next Q
Current
64
Grade C$338.54+1.1% Hist 90D α
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CRL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, CRL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($306.31) or 200D SMA ($224.03) invalidates the momentum regime and cuts Target Base ($347.68) toward Bear Floor ($271.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRL Beats Next Quarter EPS Consensus (Dec 26, 2026) & Holds Above 200D SMA”
YES 64%NO 36%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
62.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.65>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE82% OF RANGE
L: $146$338.54H: $380
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 29 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on CRL

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

0.4% ROIC with 42.0% gross margin and 3.10% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (60)

Altman-Z 3.65 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (65)

29/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like CRL
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CRL Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CRL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +96.46%🛡️ HOLDING TREND SUPPORT
2026-11-03O $376.1H $376.1L $338.5C $338.5VOL 1.50M
RES: $386.6SUP: $319.7SMA50: $306.3SMA200: $224.0
$396.0$328.3$260.6$192.9$125.2RES $386.6SUP $319.7$338.52026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRL Butterfly Map → + Track CRL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
16.8%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CRL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRL)

Health Care Rank #125 of 1015 ⚔️ ICLR vs CRL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRL vs. ICLR, MEDP, INCY, IQV)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Charles River Laboratories International Inc. (CRL) ranks #125 by composite RQD confidence (64/100, grade C) and #74 by equity capitalization ($17.16B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 88/100 (A) compared with CRL at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CRL ACTIVE
Charles River Laboratories International Inc.
C 64/100 — — 0.4% -5.81% $17.16B Benchmark Subject
ICLR
ICON plc
B 72/100 71.9x — 3.1% -2.94% $16.18B /iclr-vs-crl →
MEDP
Medpace Holdings Inc.
B+ 77/100 42.0x — 27.9% -0.59% $18.24B /medp-vs-crl →
INCY
Incyte Corp.
A 88/100 18.4x 92.8% 42.4% -0.29% $24.54B /incy-vs-crl →
IQV
IQVIA Holdings Inc.
C- 61/100 33.3x — 9.4% -3.32% $44.06B /iqv-vs-crl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-27 • CIK 0001100682 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-27), Charles River Laboratories International Inc. (CRL) reported GAAP revenue of $4.02B (-0.9% vs. FY2024 revenue of $4.05B , and -2.8% cumulative change since FY2023) , GAAP net income of -$144.3M, operating cash flow of $737.6M, and free cash flow of $557.0M (+0.8% YoY). On the balance sheet, CRL closed FY2025 with $7.14B in total assets against $1.77B in total debt (Altman Z-Score: 3.65, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-27 $4.02B -$144.3M $737.6M $557.0M $7.14B $1.77B
FY2024 (FY) 2024-12-28 $4.05B $22.2M $734.6M $552.3M $7.53B $1.81B
FY2023 (FY) 2023-12-30 $4.13B $474.6M $683.9M $498.1M $9.88B $2.31B

3. CRL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Charles River Laboratories International Inc. (NYSE: CRL) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $338.54 (-5.81% 1D, market cap $17.16B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, CRL ranks #125 in composite RQD confidence.

How does CRL compare to ICLR and MEDP in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), CRL carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 0.4%. By comparison, ICLR (ICON plc) holds a B grade (72/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.18B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRL?

Per CRL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001100682), Charles River Laboratories International Inc. generated $4.02B in revenue (-0.9% YoY), -$144.3M in net income, and $557.0M in free cash flow against $7.14B in total assets and $1.77B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRL trading relative to its 50-day, 200-day, and 52-week technical levels?

CRL last traded at $338.54 (-5.81% on volume of 1,621,096 shares), positioning the stock +10.52% above its 50-day simple moving average ($306.31) and +51.11% above its 200-day simple moving average ($224.03). Across its 52-week range of $146.20 to $379.63, CRL sits at the 82.4% percentile with a 14-day RSI of 62.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.4% ($310.10 to $366.98).

Direct Sub-Reports: CRL RQD Cockpit CRL 12M Forecast CRL Earnings & Move CRL Dividends & DRIP CRL Insiders & 13F CRL Whale Options CRL Profit Sankey CRL News & Why
ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

CRL — Charles River Laboratories International Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-27

1. Roarable Rating Brief: What This Means to a Prospective Investor

Charles River Laboratories International Inc. (CRL) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $338.54 (-5.81% 1D, market capitalization $17.16B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 0.4%, gross margin of —, operating margin of 0.6%, and free cash flow yield of 3.10%.
  • Whale 13F & Options Flow (19/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (12/20): Incorporates a 1.15x equity beta, Altman Z-Score of 3.65, Piotroski F-Score of 6/9, and Debt/Equity of 0.52x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Charles River Laboratories International Inc. (CRL) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Commercial Physical & Biological Resarch industry..0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-27), Charles River Laboratories International Inc. (CRL) reported $4.02B in annual revenue (up from $4.05B in FY2024, -0.9% YoY) and -$144.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.13B revenue, $474.6M net income) through FY2025, CRL scaled operating cash flow to $737.6M and free cash flow to $557.0M, backed by $7.14B in total assets against $1.77B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 64/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 3.10% and institutional whale pillar of 19/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $146.20 – $379.63 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 95.0x EV/EBITDA against 0.6% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Commercial Physical & Biological Resarch (Health Care), CRL carries a macro regime beta of 1.15 and gross margin of —.

  • Key Question #1: Can CRL sustain or expand its 0.6% operating margin and 0.4% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.02B and free cash flow of $557.0M, how will capital allocation balance growth reinvestment against $1.77B in total debt?
  • Key Question #3: How sensitive is CRL's 23.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

CRL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Charles River Laboratories International Inc. (CRL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRL Bull vs. Bear Conversation Board — What's Your Call at $338.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CRL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $413.32 (+15.0%)
📌 Pinned Debate

Institutional flow scores 18/20 in the RQD rating, the strongest pillar, indicating accumulation and options positioning.

Institutional flow scores 18/20 in the RQD rating, the strongest pillar, indicating accumulation and options positioning.. When you look under the hood at CRL, Fundamental Cash Engine is 13/20 with 0.0% gross margins and 0.4% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (19/20) has been quietly accumulating below $379.63. My 12M target is $413.32.

SectorRotator 🐂 BULL

@RedlineAuditor Fair point on 23.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Commercial Physical & Biological Resarch. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $291.12 (-19.0%)
Spot @ $359.41

Operating income fell from $617.3M in FY 2023 to $25.2M in FY 2025 while EV/EBITDA stands at 95 and ROIC at 0.4%.

Here is the bear case nobody on the bull side wants to address on CRL: Operating income fell from $617.3M in FY 2023 to $25.2M in FY 2025 while EV/EBITDA stands at 95 and ROIC at 0.4%.. At 23.0x forward P/E, even a small guidance miss in Biotechnology: Commercial Physical & Biological Resarch triggers a 12-15% air pocket.

LIVE TAPE